Developer docs
API playgroundTry for free, no card

Search company profiles

thymia

Full company profile

uuid0000vy8

Namestring
thymia
Legal namestring
THYMIA LIMITED
Websiteurl
thymia.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

thymia (legal entity THYMIA LIMITED, England and Wales) is a London-based voice biomarker AI company founded in 2020 that extracts clinical and wellbeing signals from natural human speech. Its core technology analyses acoustic features (pitch variation, speech rate, pauses, vocal tremor, loudness), linguistic patterns, and temporal dynamics using proprietary "Neural Morphemes™" — fundamental speech units the company claims carry biological meaning beyond words. The product portfolio comprises Helios (non-clinical wellbeing and safety monitoring), Apollo Clinical (a UKCA Class I regulated medical device for depression and anxiety assessment covering all DSM-V criteria), Sentinel and Lyra (real-time voice-agent safety monitoring that streams audio without storing recordings), and a REST API plus Activity Plugin for enterprise integration. From 15 seconds of speech, thymia's models claim to extract 30+ biomarkers at 85%+ accuracy across 11 languages, validated against gold-standard clinical benchmarks on a dataset of 75,000+ unique voices.

The company monetises via enterprise API subscriptions and Activity Plugin licensing, both priced by configurable "Wellness Check" packages on annual billing with overage mechanics and whitelabelling options; pricing is quote-based and not publicly disclosed. Go-to-market is API-first, targeting four primary verticals: healthcare systems (clinical decision support, remote patient monitoring, mental health triage), automotive OEMs (driver fatigue detection ahead of an EU July 2026 mandate), voice AI agent platforms (real-time distress detection during AI conversations), and safety-critical industries (North American first-responder agencies). Distribution is anchored by two April 2026 strategic partnerships — with Agora (real-time voice infrastructure) and Speechmatics (medical-grade ASR) — alongside direct enterprise sales and developer-led adoption via docs.thymia.ai.

As of the latest data, thymia has raised approximately USD 5.6M in total funding (USD 1.1M pre-seed in 2021, ~USD 3.07M seed in July 2023 led by Kodori AG, ~USD 1.4M Crowdcube extension in July 2023) and operates with 11–50 employees. It holds ISO 27001, ISO 13485, HIPAA, GDPR, Cyber Essentials, NHS Digital Toolkit, and Crown Commercial Service certifications, and is led by CEO and co-founder Emilia Molimpakis alongside CTO and co-founder Stefano Goria.

Short descriptiontext

thymia is a London-based voice biomarker AI company that extracts 30+ clinical and wellbeing signals — including depression, anxiety, fatigue, and cardiovascular risk — from 15 seconds of natural speech, selling API access to healthcare systems, automotive OEMs, voice AI platforms, and safety-critical industries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
voice biomarker platform, mental health assessment, clinical speech analysis, voice AI infrastructure, health detection API
Industry3 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
Product category
Voice Biomarker AI / Healthcare Speech Analytics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1API Access Subscription
TypeSubscription Recurring
Description

Customers purchase access to thymia's media API and activity plugin. Fees are determined by the number of Wellness Checks selected. The platform offers configurable data deletion options and supports whitelabelling for enterprise customers.

thymia.ai
2Activity Plugin Licensing
TypeSubscription Recurring
Description

Customers purchase access via thymia's activity plugin which may be whitelabelled or non-whitelabelled. Whitelabelling allows customers to use their own branding. Usage above agreed package limits results in overage billing.

thymia.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise API access with configurable Wellness Check packages
ModelSubscriptionBilling cadenceAnnual
Notes

Fees determined by number of Wellness Checks; overage billing for usage above package limits; systematic over usage may result in automatic upgrade to larger package

thymia.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Helios
Description

Wellbeing and safety monitoring model - detects distress, stress, fatigue, low self-esteem, and burnout in real time for healthcare, pharma, and safety-critical industries.

docs.thymia.ai
+2 more records
Core offering1 text field

thymia is a foundational voice biomarker AI platform that extracts 30+ health and wellbeing signals (depression, anxiety, fatigue, stress, cardiovascular risk, respiratory indicators, metabolic markers) from just 15 seconds of natural speech in real time. The company exposes its technology through a REST API and offers three core models: Helios for non-clinical wellbeing and safety monitoring, Apollo Clinical as a UKCA Class I regulated medical device for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI safety monitoring during live conversations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 85%+ accuracy against gold standards for health detection
+5 more records
Product overview1 text field

thymia is a foundational voice biomarker platform offering a modular product portfolio centered on extracting health signals from speech. The core offering includes three specialized models: Helios for wellbeing and safety monitoring, Apollo Clinical for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI monitoring. These are accessible via the thymia REST API, the thymia Activity Plugin for guided recording capture, and the Speechmatics-thymia Joint Platform for combined speech-to-text and biomarker intelligence. The platform processes voice at 15-second intervals, analyzing neural morphemes across acoustic, linguistic, and temporal patterns to generate 30+ clinical and wellbeing biomarker scores.

Product and service7 records
1Helios
CategoryAI Model
Description

Wellbeing and safety monitoring model detecting distress, stress, fatigue, low self-esteem, and burnout in real time across human and voice agent interactions. Designed for non-clinical settings including healthcare, pharma, and safety-critical industries.

2Apollo Clinical
CategoryRegulated Medical Device Software
Description

Clinical-grade voice-based depression and anxiety assessment covering all DSM-V criteria with disorder-level probability scores and granular symptom breakdowns. UKCA Class I regulated medical device intended for qualified healthcare professionals only. Requires two audio recordings with 15-second minimum per recording.

3Sentinel
CategoryReal-time Voice AI Infrastructure
Description

Real-time voice safety and wellbeing monitoring layer for live voice AI applications. Streams audio from existing voice stack and returns biomarker signals in real time during conversations without storing recordings. Designed for AI agents and voice platforms requiring immediate health and safety intelligence.

4Lyra
CategoryVoice Agent Monitoring
Description

Voice agent safety and monitoring product providing real-time biomarker extraction during live voice conversations. Supports custom organisation policies, demographics endpoint integration, speech progress events, and optional psyche biomarker analysis.

5thymia API
CategoryAPI Platform
Description

REST API providing programmatic access to Helios, Apollo, and Sentinel models. Enables asynchronous voice recording submission with polling for results. Supports multiple audio formats and 11 language codes. Authentication via API key.

6thymia Activity Plugin
CategoryAdd-on Module
Description

Activity-based recording capture module that hosts activities (such as read-aloud tasks or mood question responses) to collect voice recordings for model analysis. Supports whitelabelling for customer branding.

7Speechmatics-thymia Joint Platform
CategoryIntegrated Voice AI Platform
Description

Combined platform integrating Speechmatics' medical-grade speech-to-text with thymia's clinical-grade voice biomarker intelligence. Identifies 30+ health signals from 15 seconds of natural speech at over 85% accuracy.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-24
Description

Strategic partnership integrating thymia's clinically validated voice analysis technology into Agora's real-time engagement infrastructure. The collaboration enables detection of mental and physical health indicators including depression, anxiety, stress, and cardiovascular risk by analyzing 15 seconds of speech during live voice interactions. Targets healthcare, automotive, workplace wellness, and education sectors at enterprise scale.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-16
Description

Partnership combining medical-grade speech-to-text (Speechmatics) with clinical-grade voice biomarker intelligence (thymia). The joint platform identifies 30+ health signals from 15 seconds of natural speech including stress, fatigue, depression/anxiety symptoms, type 2 diabetes, and driver impairment, then acts on them in real time. Delivered through a single integration returning health signals alongside standard transcription at over 85% accuracy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sonde Health builds a voice biomarker platform that detects mental and physical health conditions from short voice samples, including depression, anxiety, and respiratory conditions. It is the closest direct competitor to thymia in clinical-grade voice biomarker SaaS for enterprise healthcare and life sciences.

TypeDirect peer
Description

Ellipsis Health uses AI vocal biomarker analysis to detect anxiety and depression in patient conversations and is deployed across US health systems. It competes head-to-head with thymia's Apollo product for healthcare-system mental-health screening contracts.

3Kintsugi
TypeDirect peer
Description

Kintsugi offers voice-based mental health screening for depression and anxiety via a short voice sample, targeting payers, providers, and digital health platforms. It is a direct comparable in product, intended use, and customer profile.

TypeDirect peer
Description

Winterlight Labs analyses speech and language patterns to detect cognitive and mental health conditions, primarily for clinical trials and pharmaceutical research. It overlaps with thymia on the underlying speech biomarker technology and clinical evidence generation, though it focuses on pharma rather than real-time enterprise deployment.

TypeBroad incumbent
Description

Hume AI provides a voice and expression AI platform measuring emotion, wellbeing, and tone in real time for developers and enterprises. It competes in the same voice-emotion AI category as thymia but offers broader emotion/wellbeing APIs rather than regulated clinical biomarkers.

TypeBroad incumbent
Description

Cogito analyses vocal cues in real time to coach call-centre agents on empathy, energy, and engagement. It is an established incumbent in voice-emotion AI for enterprise call centres, overlapping with thymia's Sentinel/Lyra use case but targeting CX rather than health.

TypeEmerging player
Description

Behavioral Signals applies emotion and sentiment analysis to voice in call-centre and conversational AI contexts. It is an emerging player in the same voice-emotion AI infrastructure category as thymia but is more focused on customer-experience analytics than regulated health biomarkers.

TypeBroad incumbent
Description

Affectiva, now part of Smart Eye, provides emotion-detection AI from face and voice for automotive and media applications. It is a broader incumbent in driver monitoring and emotion AI, overlapping with thymia's automotive use case but from a multi-modal, larger-platform perspective.

TypeEmerging player
Description

Modulate builds voice AI for real-time toxicity detection and speaker profiling in online communities and gaming. It is an adjacent emerging player in voice-emotion/character AI, sharing infrastructure-level voice intelligence customers with thymia but with a different application focus.

TypeEmerging player
Description

VoiceSense offers vocal biomarkers predicting behavioural and wellbeing traits for insurance, finance, and healthcare. It is an emerging peer in the predictive-voice-analytics space, with overlapping applicability to health and risk scoring from speech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

thymia

Voice Biomarker AI / Healthcare Speech Analyticsthymia.ai

thymia is a London-based voice biomarker AI company that extracts 30+ clinical and wellbeing signals — including depression, anxiety, fatigue, and cardiovascular risk — from 15 seconds of natural speech, selling API access to healthcare systems, automotive OEMs, voice AI platforms, and safety-critical industries.

What thymia does

thymia (legal entity THYMIA LIMITED, England and Wales) is a London-based voice biomarker AI company founded in 2020 that extracts clinical and wellbeing signals from natural human speech. Its core technology analyses acoustic features (pitch variation, speech rate, pauses, vocal tremor, loudness), linguistic patterns, and temporal dynamics using proprietary "Neural Morphemes™" — fundamental speech units the company claims carry biological meaning beyond words. The product portfolio comprises Helios (non-clinical wellbeing and safety monitoring), Apollo Clinical (a UKCA Class I regulated medical device for depression and anxiety assessment covering all DSM-V criteria), Sentinel and Lyra (real-time voice-agent safety monitoring that streams audio without storing recordings), and a REST API plus Activity Plugin for enterprise integration. From 15 seconds of speech, thymia's models claim to extract 30+ biomarkers at 85%+ accuracy across 11 languages, validated against gold-standard clinical benchmarks on a dataset of 75,000+ unique voices.

The company monetises via enterprise API subscriptions and Activity Plugin licensing, both priced by configurable "Wellness Check" packages on annual billing with overage mechanics and whitelabelling options; pricing is quote-based and not publicly disclosed. Go-to-market is API-first, targeting four primary verticals: healthcare systems (clinical decision support, remote patient monitoring, mental health triage), automotive OEMs (driver fatigue detection ahead of an EU July 2026 mandate), voice AI agent platforms (real-time distress detection during AI conversations), and safety-critical industries (North American first-responder agencies). Distribution is anchored by two April 2026 strategic partnerships — with Agora (real-time voice infrastructure) and Speechmatics (medical-grade ASR) — alongside direct enterprise sales and developer-led adoption via docs.thymia.ai.

As of the latest data, thymia has raised approximately USD 5.6M in total funding (USD 1.1M pre-seed in 2021, ~USD 3.07M seed in July 2023 led by Kodori AG, ~USD 1.4M Crowdcube extension in July 2023) and operates with 11–50 employees. It holds ISO 27001, ISO 13485, HIPAA, GDPR, Cyber Essentials, NHS Digital Toolkit, and Crown Commercial Service certifications, and is led by CEO and co-founder Emilia Molimpakis alongside CTO and co-founder Stefano Goria.

thymia firmographics

Firmographics
Name
thymia
Legal name
THYMIA LIMITED
Website
https://thymia.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
thymia is a London-based voice biomarker AI company that extracts 30+ clinical and wellbeing signals — including depression, anxiety, fatigue, and cardiovascular risk — from 15 seconds of natural speech, selling API access to healthcare systems, automotive OEMs, voice AI platforms, and safety-critical industries.
Ownership category
akta.pro rank

thymia industry classification

Industry
Product category
Voice Biomarker AI / Healthcare Speech Analytics
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Voice biomarker platform
  • Mental health assessment
  • Clinical speech analysis
  • Voice AI infrastructure
  • Health detection API

Where thymia is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

thymia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. API Access Subscription: Customers purchase access to thymia's media API and activity plugin. Fees are determined by the number of Wellness Checks selected. The platform offers configurable data deletion options and supports whitelabelling for enterprise customers.
  2. Activity Plugin Licensing: Customers purchase access via thymia's activity plugin which may be whitelabelled or non-whitelabelled. Whitelabelling allows customers to use their own branding. Usage above agreed package limits results in overage billing.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise API access with configurable Wellness Check packages

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

thymia product offering

Product offering

Core offering

thymia is a foundational voice biomarker AI platform that extracts 30+ health and wellbeing signals (depression, anxiety, fatigue, stress, cardiovascular risk, respiratory indicators, metabolic markers) from just 15 seconds of natural speech in real time. The company exposes its technology through a REST API and offers three core models: Helios for non-clinical wellbeing and safety monitoring, Apollo Clinical as a UKCA Class I regulated medical device for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI safety monitoring during live conversations.

Product overview

thymia is a foundational voice biomarker platform offering a modular product portfolio centered on extracting health signals from speech. The core offering includes three specialized models: Helios for wellbeing and safety monitoring, Apollo Clinical for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI monitoring. These are accessible via the thymia REST API, the thymia Activity Plugin for guided recording capture, and the Speechmatics-thymia Joint Platform for combined speech-to-text and biomarker intelligence. The platform processes voice at 15-second intervals, analyzing neural morphemes across acoustic, linguistic, and temporal patterns to generate 30+ clinical and wellbeing biomarker scores.

Differentiator

Problem solved

Functional benefit

Brands

  • Helios: Wellbeing and safety monitoring model - detects distress, stress, fatigue, low self-esteem, and burnout in real time for healthcare, pharma, and safety-critical industries.
  • Apollo Clinical
  • Sentinel

Products and services

  • Helios Wellbeing and safety monitoring model detecting distress, stress, fatigue, low self-esteem, and burnout in real time across human and voice agent interactions. Designed for non-clinical settings including healthcare, pharma, and safety-critical industries.
  • Apollo Clinical Clinical-grade voice-based depression and anxiety assessment covering all DSM-V criteria with disorder-level probability scores and granular symptom breakdowns. UKCA Class I regulated medical device intended for qualified healthcare professionals only. Requires two audio recordings with 15-second minimum per recording.
  • Sentinel Real-time voice safety and wellbeing monitoring layer for live voice AI applications. Streams audio from existing voice stack and returns biomarker signals in real time during conversations without storing recordings. Designed for AI agents and voice platforms requiring immediate health and safety intelligence.
  • Lyra Voice agent safety and monitoring product providing real-time biomarker extraction during live voice conversations. Supports custom organisation policies, demographics endpoint integration, speech progress events, and optional psyche biomarker analysis.
  • thymia API REST API providing programmatic access to Helios, Apollo, and Sentinel models. Enables asynchronous voice recording submission with polling for results. Supports multiple audio formats and 11 language codes. Authentication via API key.
  • thymia Activity Plugin Activity-based recording capture module that hosts activities (such as read-aloud tasks or mood question responses) to collect voice recordings for model analysis. Supports whitelabelling for customer branding.
  • Speechmatics-thymia Joint Platform Combined platform integrating Speechmatics' medical-grade speech-to-text with thymia's clinical-grade voice biomarker intelligence. Identifies 30+ health signals from 15 seconds of natural speech at over 85% accuracy.

Quantifiable outcome

  • 85%+ accuracy against gold standards for health detection
  • +5 more outcomes

Companies that use thymia

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

thymia technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

thymia partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AgoracoreTechnology or Integration · 24 April 2026Strategic partnership integrating thymia's clinically validated voice analysis technology into Agora's real-time engagement infrastructure. The collaboration enables detection of mental and physical health indicators including depression, anxiety, stress, and cardiovascular risk by analyzing 15 seconds of speech during live voice interactions. Targets healthcare, automotive, workplace wellness, and education sectors at enterprise scale.
  • SpeechmaticscoreTechnology or Integration · 16 April 2026Partnership combining medical-grade speech-to-text (Speechmatics) with clinical-grade voice biomarker intelligence (thymia). The joint platform identifies 30+ health signals from 15 seconds of natural speech including stress, fatigue, depression/anxiety symptoms, type 2 diabetes, and driver impairment, then acts on them in real time. Delivered through a single integration returning health signals alongside standard transcription at over 85% accuracy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

thymia competitors and assessment

Company assessment

Direct peers

  • Sonde Health: Sonde Health builds a voice biomarker platform that detects mental and physical health conditions from short voice samples, including depression, anxiety, and respiratory conditions. It is the closest direct competitor to thymia in clinical-grade voice biomarker SaaS for enterprise healthcare and life sciences.
  • Ellipsis Health: Ellipsis Health uses AI vocal biomarker analysis to detect anxiety and depression in patient conversations and is deployed across US health systems. It competes head-to-head with thymia's Apollo product for healthcare-system mental-health screening contracts.
  • Kintsugi: Kintsugi offers voice-based mental health screening for depression and anxiety via a short voice sample, targeting payers, providers, and digital health platforms. It is a direct comparable in product, intended use, and customer profile.
  • Winterlight Labs: Winterlight Labs analyses speech and language patterns to detect cognitive and mental health conditions, primarily for clinical trials and pharmaceutical research. It overlaps with thymia on the underlying speech biomarker technology and clinical evidence generation, though it focuses on pharma rather than real-time enterprise deployment.

Broad incumbents

  • Hume AI: Hume AI provides a voice and expression AI platform measuring emotion, wellbeing, and tone in real time for developers and enterprises. It competes in the same voice-emotion AI category as thymia but offers broader emotion/wellbeing APIs rather than regulated clinical biomarkers.
  • Cogito: Cogito analyses vocal cues in real time to coach call-centre agents on empathy, energy, and engagement. It is an established incumbent in voice-emotion AI for enterprise call centres, overlapping with thymia's Sentinel/Lyra use case but targeting CX rather than health.
  • Affectiva (Smart Eye): Affectiva, now part of Smart Eye, provides emotion-detection AI from face and voice for automotive and media applications. It is a broader incumbent in driver monitoring and emotion AI, overlapping with thymia's automotive use case but from a multi-modal, larger-platform perspective.

Emerging players

  • Behavioral Signals: Behavioral Signals applies emotion and sentiment analysis to voice in call-centre and conversational AI contexts. It is an emerging player in the same voice-emotion AI infrastructure category as thymia but is more focused on customer-experience analytics than regulated health biomarkers.
  • Modulate: Modulate builds voice AI for real-time toxicity detection and speaker profiling in online communities and gaming. It is an adjacent emerging player in voice-emotion/character AI, sharing infrastructure-level voice intelligence customers with thymia but with a different application focus.
  • VoiceSense: VoiceSense offers vocal biomarkers predicting behavioural and wellbeing traits for insurance, finance, and healthcare. It is an emerging peer in the predictive-voice-analytics space, with overlapping applicability to health and risk scoring from speech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

thymia compliance and trust

Trust signal

Compliance9 records

thymia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

thymia leadership team

Management profile

Number of profiles

Profiles2 records

thymia funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

thymia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about thymia

What does thymia do?

thymia is a foundational voice biomarker AI platform that extracts 30+ health and wellbeing signals (depression, anxiety, fatigue, stress, cardiovascular risk, respiratory indicators, metabolic markers) from just 15 seconds of natural speech in real time. The company exposes its technology through a REST API and offers three core models: Helios for non-clinical wellbeing and safety monitoring, Apollo Clinical as a UKCA Class I regulated medical device for clinical-grade depression and anxiety assessment, and Sentinel/Lyra for real-time voice AI safety monitoring during live conversations.

Is thymia a public or private company?

thymia is a private company. It is classified as venture growth investor backed and is currently operating.

When was thymia founded?

thymia was founded in 2020. It employs 11 to 50 people.

Where is thymia based?

thymia is headquartered in London, United Kingdom, in the Europe region.

How does thymia make money?

Two revenue lines are on record. API Access Subscription is the primary driver. The others are activity Plugin Licensing.

Who are thymia's main competitors?

Direct peers on record are Sonde Health, Ellipsis Health, Kintsugi and Winterlight Labs. Broad incumbents are Hume AI, Cogito and Affectiva (Smart Eye). Emerging players are Behavioral Signals, Modulate and VoiceSense.

Does thymia have an API?

Yes. REST API enabling developers to submit voice recordings and retrieve health biomarker results. Supports asynchronous recording submission via upload URLs and polling for results. Provides access to Helios (wellbeing monitoring), Apollo (clinical depression/anxiety assessment), and Sentinel (real-time voice agent safety). Authentication via API key header. Supports audio formats: FLAC, MP3, MP4, Ogg, WebM, WAV. Languages supported: en, en-AU, en-GB, en-IE, en-IN, en-US, en-ZA, es-ES, es-US, id-ID, ja-JP. Developer documentation is at docs.thymia.ai.

What industry is thymia in?

thymia's product category is Voice Biomarker AI / Healthcare Speech Analytics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAI could help screen for diabetes in seconds using speech analysisResearchers at thymia and RMIT trained AI to detect type 2 diabetes from speech, testing it on 7,319 UK participants. The model flagged higher-risk individuals 80% of the time, and 75% of those with home blood tests. The next step is clinical testing.CXOToday.comAgora and thymia Partner to Enable Real-Time Health and Safety Intelligence Across Voice CommunicationsAgora, Inc. has announced a strategic partnership with thymia, a human state voice intelligence company, to integrate clinically validated voice analysis technology into Agora's real-time engagement infrastructure. The collaboration enables the detection of mental and physical health indicators, including depression, anxiety, stress, and cardiovascular risk, by analyzing just 15 seconds of speech during live voice interactions. The technology targets healthcare, automotive, workplace wellness, and education sectors, aiming to provide real-time health and safety intelligence across voice communication platforms at enterprise scale.GlobeNewswireAgora and thymia Partner to Enable Real-Time Health and Safety Intelligence Across Voice CommunicationsAgora and thymia announced a partnership to integrate thymia's clinically validated voice intelligence into Agora's real-time conversational AI infrastructure. The integration enables real-time detection of health and safety signals from 15 seconds of speech, targeting healthcare, automotive, and workplace use cases. The collaboration aims to make voice systems understand human state in live interactions.Stock TitanAgora partners with thymia for real-time voice health AIAgora, a global leader in real-time engagement and conversational AI, announced a strategic partnership with thymia, a human state voice intelligence company, to deploy clinically validated voice health analysis at global scale. The collaboration combines Agora's low-latency real-time infrastructure with thymia's AI models that extract health biomarkers—including depression, anxiety, stress, and cardiovascular risk—from 15 seconds of speech, targeting healthcare, automotive, workplace wellness, and education applications.YahooAgora and thymia Partner to Enable Real-Time Health and Safety Intelligence Across Voice CommunicationsAgora, Inc. (NASDAQ: API), a global leader in real-time engagement and conversational AI infrastructure, announced a strategic partnership with thymia, a human state voice intelligence company, to deploy clinically validated voice intelligence at global scale across voice communications. The collaboration integrates thymia's AI models that extract 30+ clinical-grade biomarkers—including markers for depression, anxiety, stress, and cardiovascular risk—from just 15 seconds of speech with Agora's real-time engagement platform processing over 80 billion minutes of engagement monthly. The partnership targets healthcare, automotive, workplace wellness, and education sectors, enabling real-time health and safety awareness in live voice interactions.GlobeNewswireAI can now understand health signals from 15 seconds of your voice, including type 2 diabetes, fatigue and stressSpeechmatics and thymia announced a joint platform that identifies 30+ health signals from 15 seconds of natural speech, including stress, fatigue, and type 2 diabetes. The system delivers health signals alongside transcription at over 85% accuracy, with thymia's technology validated in 20+ peer-reviewed publications. The partnership will launch at THE VOICE AI HACK this weekend.MabinogiCrowdcube Investment Video Creators Mabinogi Help Thymia raise £1.11M! - MabinogiMabinogi Productions created video content for Thymia's Crowdcube campaign, which successfully raised £1.11 million from over 430 investors. The company utilized A/B testing of different video angles to attract high-value investors, leading to an additional £2.8 million in VC backing and ongoing use of the content for branding.Business InsiderThymia uses AI to assess and track patients' mental health conditions. Check out the 9-slide deck it used to secure $2.7 million.Thymia, a London-based startup, raised $2.7 million in funding led by Kodori Ventures. Its AI platform assesses depression and anxiety using voice, video, and behavior data from over 6,000 participants. The company will use the funds to pursue UK Class 1 medical device certification and expand its AI team.FinSMEsthymia Raises $2.7M in Seed FundingLondon-based healthtech startup thymia raised $2.7 million in seed funding, bringing its total capitalization to $3.5 million, with the round led by Kodori Ventures and participation from investors such as Entrepreneur First and Form Ventures. The company plans to utilize these funds to expand the reach of its AI-driven platform, which uses gamified neuropsychological tests to diagnose and monitor mental health conditions. Thymia is currently deploying its technology across the UK, US, Spain, Brazil, Indonesia, and Nigeria, with further international expansion planned.